ADM personal page - To The Moon

ADM

No personal profile

14Follow

1Followers

2Topic

0Badge

10-23

Share your opinion about this news…

Earning Preview: ResMed Q1 revenue is expected to increase by 4.60%, and institutional views are bullish

2024-10-04

Share your opinion about this news…

Sorry, the original content has been removed

2024-10-04

Share your opinion about this news…

Sorry, the original content has been removed

2024-09-11

$ANZ GROUP HOLDINGS LTD(ANZ.AU)$

2024-09-11

$ANZ GROUP HOLDINGS LTD(ANZ.AU)$

2024-06-03

$ANZ GROUP HOLDINGS LTD(ANZ.AU)$

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4114240648215622","uuid":"4114240648215622","gmtCreate":1651207436222,"gmtModify":1651207436222,"name":"ADM","pinyin":"adm","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":14,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":2,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.06.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":621388042699056,"gmtCreate":1792731777413,"gmtModify":1792731780179,"author":{"id":"4114240648215622","authorId":"4114240648215622","name":"ADM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4114240648215622","idStr":"4114240648215622"},"themes":[],"title":"","htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/621388042699056","repostId":"1194368123","repostType":2,"repost":{"id":"1194368123","kind":"news","weMediaInfo":{"introduction":"Focus on earnings forecast and in-depth analysis","home_visible":1,"media_name":"Earnings Agent","id":"1025659746","head_image":"https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f"},"pubTimestamp":1792687296,"share":"https://ttm.financial/m/news/1194368123?lang=en_US&edition=fundamental","pubTime":"2026-10-23 00:41","market":"hk","language":"en","title":"Earning Preview: ResMed Q1 revenue is expected to increase by 4.60%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1194368123","media":"Earnings Agent","summary":"Abstract ResMed will release first-quarter fiscal 2027 results on October 29, 2026 after market close (Post-Mkt), with investor attention centered on revenue growth, margin trajectory, and the pace...","content":"<p><h2><b>Abstract</b></h2>\nResMed will release first-quarter fiscal 2027 results on October 29, 2026 after market close (Post-Mkt), with investor attention centered on revenue growth, margin trajectory, and the pace of adjusted EPS expansion.</p>\n<p><h2><b>Market Forecast</b></h2>\nMarket expectations for the current quarter call for revenue of 1.39 billion US dollars, up 4.60% year over year, adjusted EPS of 2.67 (up 4.65% year over year), and EBIT of 471.33 million US dollars (up 1.64% year over year). Based on the previous report and recent commentary, consensus anticipates stable-to-improving profitability supported by mix and cost controls, though formal guidance for gross margin or net margin has not been issued for this quarter.</p>\n<p>ResMed’s core product engine remains anchored by the Sleep and Respiratory Care franchise, with ongoing product refresh and consumables momentum expected to support steady demand and recurring revenue from masks and supplies. The software services and digital ecosystem are the most promising segments for longer-term compounding, with last quarter’s software revenue at 172.00 million US dollars and continued product development intended to lift engagement and adherence.</p>\n<p><h2><b>Last Quarter Review</b></h2>\nIn the prior quarter, ResMed reported revenue of 1.46 billion US dollars (up 8.58% year over year), a gross profit margin of 59.41%, GAAP net profit attributable to the parent of 383.00 million US dollars, a net profit margin of 26.20%, and adjusted EPS of 2.95 (up 15.69% year over year). The company demonstrated solid operational leverage and expense discipline, which, together with revenue growth, supported the expansion in adjusted EPS.</p>\n<p>Main business momentum remained balanced: Sleep and Respiratory Care revenue reached 1.29 billion US dollars and software services delivered 172.00 million US dollars, together contributing to the 8.58% overall revenue growth and supporting resilient margins.</p>\n<p><h2><b>Current Quarter Outlook</b></h2>\n<h3><b>Sleep and Respiratory Care: Product refresh and consumables underpin recurring demand</b></h3>\nResMed’s Sleep and Respiratory Care business is poised for a seasonally normal step-down in revenue from the fiscal fourth quarter to the fiscal first quarter, with consensus projecting 1.39 billion US dollars for the current period. Product momentum is anchored by both device placements and growing consumables utilization, aided by continuous portfolio updates. The near-term catalyst set for October 28—the launch of the AirTouch F40 mask—introduces a fabric-cushioned interface designed to improve comfort and adherence; improved adherence often correlates with higher 90-day compliance rates and stronger replenishment of masks and accessories.</p>\n<p>From a margin standpoint, last quarter’s 59.41% gross profit margin reflected favorable mix and ongoing cost control. For the to-be-reported quarter, investors will look for confirmation that component cost normalization and premium-priced interfaces can help sustain margin resilience despite typical early-year seasonality. The balance between device ASPs, consumables replenishment, and logistics costs will be central to maintaining net profit and adjusted EPS trajectories. While formal guidance for gross and net margins is absent for this quarter, the market’s EBIT and EPS growth expectations imply cautious confidence in holding or modestly improving profitability.</p>\n<p>Commercially, ResMed continues to emphasize ease of use, adherence tools, and portfolio breadth to support consistent therapy engagement. The AirSense 11 family, alongside targeted mask innovations, aims to raise patient comfort and reduce abandonment. In this quarter, the incremental benefit from the F40’s introduction is expected to be modest in absolute revenue terms but meaningful in signaling a continued refresh cycle designed to reinforce the consumables revenue base.</p>\n<p><h3><b>Software and Digital Ecosystem: Focus sharpened, engagement metrics improving</b></h3>\nThe company’s software-related and digital capabilities form an increasingly important pillar of revenue quality and predictability. Last quarter’s software services revenue was 172.00 million US dollars, and the strategic simplification of the software portfolio—highlighted by the divestiture of MatrixCare—has been flagged by the buy-side and sell-side as a positive step to sharpen focus on higher-synergy, core-adjacent SaaS assets. These digital tools are designed to integrate patient engagement (via patient-facing apps) with clinician oversight (via remote monitoring platforms), creating a differentiated adherence and service loop.</p>\n<p>In the near term, the market will watch for expanding attach rates of digital services to the installed base of connected devices and masks. Even incremental improvements in adherence have a compounding effect: higher therapy compliance can lift ongoing use of masks and supplies, translating into recurring revenue momentum. The current quarter’s forecasted EPS growth of 4.65% year over year implicitly assumes continued benefits from this digital engagement model, even as headline revenue growth moderates into the mid-single digits.</p>\n<p>Operationally, a more focused software stack can also streamline go-to-market priorities, potentially improving gross margin mix by emphasizing subscription-like revenue with supportive unit economics. While formal margin guidance for software is not disclosed for the quarter, investor expectations appear to be aligned to steady growth with disciplined expense management. Over time, consistent software adoption across geographies and payer channels could help reduce variability in total company margins by stabilizing revenue streams tied to patient adherence and care management.</p>\n<p><h3><b>Key Stock Drivers This Quarter: Margin trajectory, recall headwinds, and capital deployment</b></h3>\nThree factors appear most likely to influence the stock’s performance around the print. First, margin trajectory remains a primary focus. With last quarter’s gross margin at 59.41%, the market will look for stable to slightly improved levels driven by mix (masks and supplies), selective pricing, and supply-chain tailwinds. The consensus EPS and EBIT growth rates—4.65% and 1.64% year over year respectively—imply a conservative stance on operating leverage, leaving room for upside if cost normalization proves faster or if the mix skews more favorably toward higher-margin consumables.</p>\n<p>Second, the reported class I recall affecting Astral ventilators and the subsequent decision to halt that product line for fiscal 2027 introduces a known revenue headwind. Public commentary has indicated an estimated full-year revenue impact of approximately 75.00 million US dollars related to the halt. Investors will monitor whether the company has effectively ringfenced this issue—both in revenue impact and in remediation costs—and how the product gap will be managed within the broader portfolio. While the Astral line is not the core driver of quarterly revenue, clarity on replacement strategies, timing for remediation, and the potential redeployment of resources can influence sentiment and valuation multiples.</p>\n<p>Third, capital allocation moves, particularly the 450.00 million US dollars accelerated share repurchase, play into per-share metrics and investor confidence. In the absence of a formal quarterly guidance regime, buybacks can provide support to EPS outcomes and signal conviction in medium-term cash generation. For the current quarter, the pacing and accounting of the ASR arrangement will be watched, as will any updates on the remaining authorization capacity and future repurchase intentions. Together with operating execution, capital returns shape the path of adjusted EPS and the implied free cash flow profile underpinning equity valuation.</p>\n<p>Beyond these drivers, leadership continuity and governance updates matter. Announced board changes, including the appointment of a lead director and planned retirement of a long-serving director, have been absorbed without material controversy. Investors will also track any CFO-related updates or transitions following prior retirement announcements in earlier periods, with a focus on continuity in financial policy and comfort with external stakeholder communications.</p>\n<p><h2><b>Analyst Opinions</b></h2>\nAcross recently published views in the last six months, bullish opinions outnumber bearish ones. Multiple firms have maintained or raised positive stances, citing improving gross margin trajectory, disciplined expense control, and a clearer software strategy post-portfolio streamlining. A renewed focus on core adjacencies and recurring-consumables momentum features prominently in the positive theses, with most bulls modeling mid-single-digit revenue growth and high-single-digit EPS growth over the next several years.</p>\n<p>RBC Capital Markets upgraded the shares to Outperform and highlighted a pathway to high-single-digit EPS growth over the medium term, even accounting for a potential competitive landscape shift in later fiscal years. Their constructive stance emphasized incremental gross margin recovery and solid execution in masks and supplies. This upgrade followed their earlier, more cautious posture, and signals a tangible change in conviction as margins stabilize and operating discipline improves.</p>\n<p>William Blair reiterated a Buy rating, pointing to the strategic rationale of the recent software portfolio actions, including the MatrixCare divestiture. Their view underscores a sharpened SaaS growth outlook and suggests that a tighter focus on core digital offerings can lead to more durable engagement and monetization. They also see valuation supported by the company’s recurring revenue base and the potential accretion from capital returns, including the accelerated share repurchase.</p>\n<p>KeyBanc reaffirmed an Overweight rating and raised its price target, reflecting confidence in the company’s margin and earnings trajectory. Their framework assigns value to the combined effect of improving product mix, continued device placements, and a sticky consumables stream. Baird similarly lifted its price target while keeping a positive stance, aligning with the broader bullish narrative centered on margin resilience and a product cycle that remains supportive of steady revenue growth.</p>\n<p>Neutral stances from Morgan Stanley, Citigroup, and Redburn indicate a wait-and-see approach, primarily tied to macro uncertainties, product-cycle timing, and recall-related noise. However, the absence of fresh negative calls and the presence of multiple upgrades and reaffirmations suggest that the center of gravity in the coverage universe leans constructive. The distribution of sentiment in our compiled set indicates the bull case as the majority position, with neutral voices forming the balance and little explicit bearishness currently present.</p>\n<p>In context of the to-be-reported quarter, the bullish cohort expects ResMed to deliver on the modest consensus bar—revenue growth of 4.60% year over year to 1.39 billion US dollars and adjusted EPS of 2.67, up 4.65% year over year—while demonstrating continued progress on margin stability and proof points in digital engagement. They also anticipate that the early-stage introduction of the AirTouch F40 mask could serve as a near-term signal for the ongoing consumables refresh cycle, with incremental benefits flowing more meaningfully over subsequent quarters. Additionally, the ASR is seen as a supportive factor for per-share metrics, complementing operating results.</p>\n<p>Taken together, the dominant institutional view is that ResMed is positioned to navigate the quarter’s headwinds and deliver in-line-to-slightly-better outcomes on profitability, with upside skew depending on the mix of consumables and the cadence of cost normalization. The majority stance frames the stock’s near-term setup as balanced-to-positive, contingent on reaffirming the gross margin progress seen last quarter and demonstrating steady execution in both Sleep and Respiratory Care and the digital ecosystem.</p>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Earning Preview: ResMed Q1 revenue is expected to increase by 4.60%, and institutional views are bullish</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEarning Preview: ResMed Q1 revenue is expected to increase by 4.60%, and institutional views are bullish\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1025659746\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Earnings Agent </p>\n<p class=\"h-time\">2026-10-23 00:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><h2><b>Abstract</b></h2>\nResMed will release first-quarter fiscal 2027 results on October 29, 2026 after market close (Post-Mkt), with investor attention centered on revenue growth, margin trajectory, and the pace of adjusted EPS expansion.</p>\n<p><h2><b>Market Forecast</b></h2>\nMarket expectations for the current quarter call for revenue of 1.39 billion US dollars, up 4.60% year over year, adjusted EPS of 2.67 (up 4.65% year over year), and EBIT of 471.33 million US dollars (up 1.64% year over year). Based on the previous report and recent commentary, consensus anticipates stable-to-improving profitability supported by mix and cost controls, though formal guidance for gross margin or net margin has not been issued for this quarter.</p>\n<p>ResMed’s core product engine remains anchored by the Sleep and Respiratory Care franchise, with ongoing product refresh and consumables momentum expected to support steady demand and recurring revenue from masks and supplies. The software services and digital ecosystem are the most promising segments for longer-term compounding, with last quarter’s software revenue at 172.00 million US dollars and continued product development intended to lift engagement and adherence.</p>\n<p><h2><b>Last Quarter Review</b></h2>\nIn the prior quarter, ResMed reported revenue of 1.46 billion US dollars (up 8.58% year over year), a gross profit margin of 59.41%, GAAP net profit attributable to the parent of 383.00 million US dollars, a net profit margin of 26.20%, and adjusted EPS of 2.95 (up 15.69% year over year). The company demonstrated solid operational leverage and expense discipline, which, together with revenue growth, supported the expansion in adjusted EPS.</p>\n<p>Main business momentum remained balanced: Sleep and Respiratory Care revenue reached 1.29 billion US dollars and software services delivered 172.00 million US dollars, together contributing to the 8.58% overall revenue growth and supporting resilient margins.</p>\n<p><h2><b>Current Quarter Outlook</b></h2>\n<h3><b>Sleep and Respiratory Care: Product refresh and consumables underpin recurring demand</b></h3>\nResMed’s Sleep and Respiratory Care business is poised for a seasonally normal step-down in revenue from the fiscal fourth quarter to the fiscal first quarter, with consensus projecting 1.39 billion US dollars for the current period. Product momentum is anchored by both device placements and growing consumables utilization, aided by continuous portfolio updates. The near-term catalyst set for October 28—the launch of the AirTouch F40 mask—introduces a fabric-cushioned interface designed to improve comfort and adherence; improved adherence often correlates with higher 90-day compliance rates and stronger replenishment of masks and accessories.</p>\n<p>From a margin standpoint, last quarter’s 59.41% gross profit margin reflected favorable mix and ongoing cost control. For the to-be-reported quarter, investors will look for confirmation that component cost normalization and premium-priced interfaces can help sustain margin resilience despite typical early-year seasonality. The balance between device ASPs, consumables replenishment, and logistics costs will be central to maintaining net profit and adjusted EPS trajectories. While formal guidance for gross and net margins is absent for this quarter, the market’s EBIT and EPS growth expectations imply cautious confidence in holding or modestly improving profitability.</p>\n<p>Commercially, ResMed continues to emphasize ease of use, adherence tools, and portfolio breadth to support consistent therapy engagement. The AirSense 11 family, alongside targeted mask innovations, aims to raise patient comfort and reduce abandonment. In this quarter, the incremental benefit from the F40’s introduction is expected to be modest in absolute revenue terms but meaningful in signaling a continued refresh cycle designed to reinforce the consumables revenue base.</p>\n<p><h3><b>Software and Digital Ecosystem: Focus sharpened, engagement metrics improving</b></h3>\nThe company’s software-related and digital capabilities form an increasingly important pillar of revenue quality and predictability. Last quarter’s software services revenue was 172.00 million US dollars, and the strategic simplification of the software portfolio—highlighted by the divestiture of MatrixCare—has been flagged by the buy-side and sell-side as a positive step to sharpen focus on higher-synergy, core-adjacent SaaS assets. These digital tools are designed to integrate patient engagement (via patient-facing apps) with clinician oversight (via remote monitoring platforms), creating a differentiated adherence and service loop.</p>\n<p>In the near term, the market will watch for expanding attach rates of digital services to the installed base of connected devices and masks. Even incremental improvements in adherence have a compounding effect: higher therapy compliance can lift ongoing use of masks and supplies, translating into recurring revenue momentum. The current quarter’s forecasted EPS growth of 4.65% year over year implicitly assumes continued benefits from this digital engagement model, even as headline revenue growth moderates into the mid-single digits.</p>\n<p>Operationally, a more focused software stack can also streamline go-to-market priorities, potentially improving gross margin mix by emphasizing subscription-like revenue with supportive unit economics. While formal margin guidance for software is not disclosed for the quarter, investor expectations appear to be aligned to steady growth with disciplined expense management. Over time, consistent software adoption across geographies and payer channels could help reduce variability in total company margins by stabilizing revenue streams tied to patient adherence and care management.</p>\n<p><h3><b>Key Stock Drivers This Quarter: Margin trajectory, recall headwinds, and capital deployment</b></h3>\nThree factors appear most likely to influence the stock’s performance around the print. First, margin trajectory remains a primary focus. With last quarter’s gross margin at 59.41%, the market will look for stable to slightly improved levels driven by mix (masks and supplies), selective pricing, and supply-chain tailwinds. The consensus EPS and EBIT growth rates—4.65% and 1.64% year over year respectively—imply a conservative stance on operating leverage, leaving room for upside if cost normalization proves faster or if the mix skews more favorably toward higher-margin consumables.</p>\n<p>Second, the reported class I recall affecting Astral ventilators and the subsequent decision to halt that product line for fiscal 2027 introduces a known revenue headwind. Public commentary has indicated an estimated full-year revenue impact of approximately 75.00 million US dollars related to the halt. Investors will monitor whether the company has effectively ringfenced this issue—both in revenue impact and in remediation costs—and how the product gap will be managed within the broader portfolio. While the Astral line is not the core driver of quarterly revenue, clarity on replacement strategies, timing for remediation, and the potential redeployment of resources can influence sentiment and valuation multiples.</p>\n<p>Third, capital allocation moves, particularly the 450.00 million US dollars accelerated share repurchase, play into per-share metrics and investor confidence. In the absence of a formal quarterly guidance regime, buybacks can provide support to EPS outcomes and signal conviction in medium-term cash generation. For the current quarter, the pacing and accounting of the ASR arrangement will be watched, as will any updates on the remaining authorization capacity and future repurchase intentions. Together with operating execution, capital returns shape the path of adjusted EPS and the implied free cash flow profile underpinning equity valuation.</p>\n<p>Beyond these drivers, leadership continuity and governance updates matter. Announced board changes, including the appointment of a lead director and planned retirement of a long-serving director, have been absorbed without material controversy. Investors will also track any CFO-related updates or transitions following prior retirement announcements in earlier periods, with a focus on continuity in financial policy and comfort with external stakeholder communications.</p>\n<p><h2><b>Analyst Opinions</b></h2>\nAcross recently published views in the last six months, bullish opinions outnumber bearish ones. Multiple firms have maintained or raised positive stances, citing improving gross margin trajectory, disciplined expense control, and a clearer software strategy post-portfolio streamlining. A renewed focus on core adjacencies and recurring-consumables momentum features prominently in the positive theses, with most bulls modeling mid-single-digit revenue growth and high-single-digit EPS growth over the next several years.</p>\n<p>RBC Capital Markets upgraded the shares to Outperform and highlighted a pathway to high-single-digit EPS growth over the medium term, even accounting for a potential competitive landscape shift in later fiscal years. Their constructive stance emphasized incremental gross margin recovery and solid execution in masks and supplies. This upgrade followed their earlier, more cautious posture, and signals a tangible change in conviction as margins stabilize and operating discipline improves.</p>\n<p>William Blair reiterated a Buy rating, pointing to the strategic rationale of the recent software portfolio actions, including the MatrixCare divestiture. Their view underscores a sharpened SaaS growth outlook and suggests that a tighter focus on core digital offerings can lead to more durable engagement and monetization. They also see valuation supported by the company’s recurring revenue base and the potential accretion from capital returns, including the accelerated share repurchase.</p>\n<p>KeyBanc reaffirmed an Overweight rating and raised its price target, reflecting confidence in the company’s margin and earnings trajectory. Their framework assigns value to the combined effect of improving product mix, continued device placements, and a sticky consumables stream. Baird similarly lifted its price target while keeping a positive stance, aligning with the broader bullish narrative centered on margin resilience and a product cycle that remains supportive of steady revenue growth.</p>\n<p>Neutral stances from Morgan Stanley, Citigroup, and Redburn indicate a wait-and-see approach, primarily tied to macro uncertainties, product-cycle timing, and recall-related noise. However, the absence of fresh negative calls and the presence of multiple upgrades and reaffirmations suggest that the center of gravity in the coverage universe leans constructive. The distribution of sentiment in our compiled set indicates the bull case as the majority position, with neutral voices forming the balance and little explicit bearishness currently present.</p>\n<p>In context of the to-be-reported quarter, the bullish cohort expects ResMed to deliver on the modest consensus bar—revenue growth of 4.60% year over year to 1.39 billion US dollars and adjusted EPS of 2.67, up 4.65% year over year—while demonstrating continued progress on margin stability and proof points in digital engagement. They also anticipate that the early-stage introduction of the AirTouch F40 mask could serve as a near-term signal for the ongoing consumables refresh cycle, with incremental benefits flowing more meaningfully over subsequent quarters. Additionally, the ASR is seen as a supportive factor for per-share metrics, complementing operating results.</p>\n<p>Taken together, the dominant institutional view is that ResMed is positioned to navigate the quarter’s headwinds and deliver in-line-to-slightly-better outcomes on profitability, with upside skew depending on the mix of consumables and the cadence of cost normalization. The majority stance frames the stock’s near-term setup as balanced-to-positive, contingent on reaffirming the gross margin progress seen last quarter and demonstrating steady execution in both Sleep and Respiratory Care and the digital ecosystem.</p>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RMD":"瑞思迈"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194368123","content_text":"Abstract\nResMed will release first-quarter fiscal 2027 results on October 29, 2026 after market close (Post-Mkt), with investor attention centered on revenue growth, margin trajectory, and the pace of adjusted EPS expansion.\nMarket Forecast\nMarket expectations for the current quarter call for revenue of 1.39 billion US dollars, up 4.60% year over year, adjusted EPS of 2.67 (up 4.65% year over year), and EBIT of 471.33 million US dollars (up 1.64% year over year). Based on the previous report and recent commentary, consensus anticipates stable-to-improving profitability supported by mix and cost controls, though formal guidance for gross margin or net margin has not been issued for this quarter.\nResMed’s core product engine remains anchored by the Sleep and Respiratory Care franchise, with ongoing product refresh and consumables momentum expected to support steady demand and recurring revenue from masks and supplies. The software services and digital ecosystem are the most promising segments for longer-term compounding, with last quarter’s software revenue at 172.00 million US dollars and continued product development intended to lift engagement and adherence.\nLast Quarter Review\nIn the prior quarter, ResMed reported revenue of 1.46 billion US dollars (up 8.58% year over year), a gross profit margin of 59.41%, GAAP net profit attributable to the parent of 383.00 million US dollars, a net profit margin of 26.20%, and adjusted EPS of 2.95 (up 15.69% year over year). The company demonstrated solid operational leverage and expense discipline, which, together with revenue growth, supported the expansion in adjusted EPS.\nMain business momentum remained balanced: Sleep and Respiratory Care revenue reached 1.29 billion US dollars and software services delivered 172.00 million US dollars, together contributing to the 8.58% overall revenue growth and supporting resilient margins.\nCurrent Quarter Outlook\nSleep and Respiratory Care: Product refresh and consumables underpin recurring demand\nResMed’s Sleep and Respiratory Care business is poised for a seasonally normal step-down in revenue from the fiscal fourth quarter to the fiscal first quarter, with consensus projecting 1.39 billion US dollars for the current period. Product momentum is anchored by both device placements and growing consumables utilization, aided by continuous portfolio updates. The near-term catalyst set for October 28—the launch of the AirTouch F40 mask—introduces a fabric-cushioned interface designed to improve comfort and adherence; improved adherence often correlates with higher 90-day compliance rates and stronger replenishment of masks and accessories.\nFrom a margin standpoint, last quarter’s 59.41% gross profit margin reflected favorable mix and ongoing cost control. For the to-be-reported quarter, investors will look for confirmation that component cost normalization and premium-priced interfaces can help sustain margin resilience despite typical early-year seasonality. The balance between device ASPs, consumables replenishment, and logistics costs will be central to maintaining net profit and adjusted EPS trajectories. While formal guidance for gross and net margins is absent for this quarter, the market’s EBIT and EPS growth expectations imply cautious confidence in holding or modestly improving profitability.\nCommercially, ResMed continues to emphasize ease of use, adherence tools, and portfolio breadth to support consistent therapy engagement. The AirSense 11 family, alongside targeted mask innovations, aims to raise patient comfort and reduce abandonment. In this quarter, the incremental benefit from the F40’s introduction is expected to be modest in absolute revenue terms but meaningful in signaling a continued refresh cycle designed to reinforce the consumables revenue base.\nSoftware and Digital Ecosystem: Focus sharpened, engagement metrics improving\nThe company’s software-related and digital capabilities form an increasingly important pillar of revenue quality and predictability. Last quarter’s software services revenue was 172.00 million US dollars, and the strategic simplification of the software portfolio—highlighted by the divestiture of MatrixCare—has been flagged by the buy-side and sell-side as a positive step to sharpen focus on higher-synergy, core-adjacent SaaS assets. These digital tools are designed to integrate patient engagement (via patient-facing apps) with clinician oversight (via remote monitoring platforms), creating a differentiated adherence and service loop.\nIn the near term, the market will watch for expanding attach rates of digital services to the installed base of connected devices and masks. Even incremental improvements in adherence have a compounding effect: higher therapy compliance can lift ongoing use of masks and supplies, translating into recurring revenue momentum. The current quarter’s forecasted EPS growth of 4.65% year over year implicitly assumes continued benefits from this digital engagement model, even as headline revenue growth moderates into the mid-single digits.\nOperationally, a more focused software stack can also streamline go-to-market priorities, potentially improving gross margin mix by emphasizing subscription-like revenue with supportive unit economics. While formal margin guidance for software is not disclosed for the quarter, investor expectations appear to be aligned to steady growth with disciplined expense management. Over time, consistent software adoption across geographies and payer channels could help reduce variability in total company margins by stabilizing revenue streams tied to patient adherence and care management.\nKey Stock Drivers This Quarter: Margin trajectory, recall headwinds, and capital deployment\nThree factors appear most likely to influence the stock’s performance around the print. First, margin trajectory remains a primary focus. With last quarter’s gross margin at 59.41%, the market will look for stable to slightly improved levels driven by mix (masks and supplies), selective pricing, and supply-chain tailwinds. The consensus EPS and EBIT growth rates—4.65% and 1.64% year over year respectively—imply a conservative stance on operating leverage, leaving room for upside if cost normalization proves faster or if the mix skews more favorably toward higher-margin consumables.\nSecond, the reported class I recall affecting Astral ventilators and the subsequent decision to halt that product line for fiscal 2027 introduces a known revenue headwind. Public commentary has indicated an estimated full-year revenue impact of approximately 75.00 million US dollars related to the halt. Investors will monitor whether the company has effectively ringfenced this issue—both in revenue impact and in remediation costs—and how the product gap will be managed within the broader portfolio. While the Astral line is not the core driver of quarterly revenue, clarity on replacement strategies, timing for remediation, and the potential redeployment of resources can influence sentiment and valuation multiples.\nThird, capital allocation moves, particularly the 450.00 million US dollars accelerated share repurchase, play into per-share metrics and investor confidence. In the absence of a formal quarterly guidance regime, buybacks can provide support to EPS outcomes and signal conviction in medium-term cash generation. For the current quarter, the pacing and accounting of the ASR arrangement will be watched, as will any updates on the remaining authorization capacity and future repurchase intentions. Together with operating execution, capital returns shape the path of adjusted EPS and the implied free cash flow profile underpinning equity valuation.\nBeyond these drivers, leadership continuity and governance updates matter. Announced board changes, including the appointment of a lead director and planned retirement of a long-serving director, have been absorbed without material controversy. Investors will also track any CFO-related updates or transitions following prior retirement announcements in earlier periods, with a focus on continuity in financial policy and comfort with external stakeholder communications.\nAnalyst Opinions\nAcross recently published views in the last six months, bullish opinions outnumber bearish ones. Multiple firms have maintained or raised positive stances, citing improving gross margin trajectory, disciplined expense control, and a clearer software strategy post-portfolio streamlining. A renewed focus on core adjacencies and recurring-consumables momentum features prominently in the positive theses, with most bulls modeling mid-single-digit revenue growth and high-single-digit EPS growth over the next several years.\nRBC Capital Markets upgraded the shares to Outperform and highlighted a pathway to high-single-digit EPS growth over the medium term, even accounting for a potential competitive landscape shift in later fiscal years. Their constructive stance emphasized incremental gross margin recovery and solid execution in masks and supplies. This upgrade followed their earlier, more cautious posture, and signals a tangible change in conviction as margins stabilize and operating discipline improves.\nWilliam Blair reiterated a Buy rating, pointing to the strategic rationale of the recent software portfolio actions, including the MatrixCare divestiture. Their view underscores a sharpened SaaS growth outlook and suggests that a tighter focus on core digital offerings can lead to more durable engagement and monetization. They also see valuation supported by the company’s recurring revenue base and the potential accretion from capital returns, including the accelerated share repurchase.\nKeyBanc reaffirmed an Overweight rating and raised its price target, reflecting confidence in the company’s margin and earnings trajectory. Their framework assigns value to the combined effect of improving product mix, continued device placements, and a sticky consumables stream. Baird similarly lifted its price target while keeping a positive stance, aligning with the broader bullish narrative centered on margin resilience and a product cycle that remains supportive of steady revenue growth.\nNeutral stances from Morgan Stanley, Citigroup, and Redburn indicate a wait-and-see approach, primarily tied to macro uncertainties, product-cycle timing, and recall-related noise. However, the absence of fresh negative calls and the presence of multiple upgrades and reaffirmations suggest that the center of gravity in the coverage universe leans constructive. The distribution of sentiment in our compiled set indicates the bull case as the majority position, with neutral voices forming the balance and little explicit bearishness currently present.\nIn context of the to-be-reported quarter, the bullish cohort expects ResMed to deliver on the modest consensus bar—revenue growth of 4.60% year over year to 1.39 billion US dollars and adjusted EPS of 2.67, up 4.65% year over year—while demonstrating continued progress on margin stability and proof points in digital engagement. They also anticipate that the early-stage introduction of the AirTouch F40 mask could serve as a near-term signal for the ongoing consumables refresh cycle, with incremental benefits flowing more meaningfully over subsequent quarters. Additionally, the ASR is seen as a supportive factor for per-share metrics, complementing operating results.\nTaken together, the dominant institutional view is that ResMed is positioned to navigate the quarter’s headwinds and deliver in-line-to-slightly-better outcomes on profitability, with upside skew depending on the mix of consumables and the cadence of cost normalization. The majority stance frames the stock’s near-term setup as balanced-to-positive, contingent on reaffirming the gross margin progress seen last quarter and demonstrating steady execution in both Sleep and Respiratory Care and the digital ecosystem.","news_type":1,"symbols_score_info":{"RMD":1}},"isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":356332767183088,"gmtCreate":1728004779183,"gmtModify":1728004781545,"author":{"id":"4114240648215622","authorId":"4114240648215622","name":"ADM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4114240648215622","idStr":"4114240648215622"},"themes":[],"title":"","htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/356332767183088","repostId":"2472864773","repostType":2,"isVote":1,"tweetType":1,"viewCount":1254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":356331204743312,"gmtCreate":1728004480911,"gmtModify":1728006360250,"author":{"id":"4114240648215622","authorId":"4114240648215622","name":"ADM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4114240648215622","idStr":"4114240648215622"},"themes":[],"title":"","htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/356331204743312","repostId":"2472864773","repostType":2,"isVote":1,"tweetType":1,"viewCount":1021,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":348282003079272,"gmtCreate":1726035917488,"gmtModify":1726037056035,"author":{"id":"4114240648215622","authorId":"4114240648215622","name":"ADM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4114240648215622","idStr":"4114240648215622"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/ANZ.AU\">$ANZ GROUP HOLDINGS LTD(ANZ.AU)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/ANZ.AU\">$ANZ GROUP HOLDINGS LTD(ANZ.AU)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$ANZ GROUP HOLDINGS LTD(ANZ.AU)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/348282003079272","isVote":1,"tweetType":1,"viewCount":1570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":348282324160656,"gmtCreate":1726035906464,"gmtModify":1726035923992,"author":{"id":"4114240648215622","authorId":"4114240648215622","name":"ADM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4114240648215622","idStr":"4114240648215622"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/ANZ.AU\">$ANZ GROUP HOLDINGS LTD(ANZ.AU)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/ANZ.AU\">$ANZ GROUP HOLDINGS LTD(ANZ.AU)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$ANZ GROUP HOLDINGS LTD(ANZ.AU)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/348282324160656","isVote":1,"tweetType":1,"viewCount":1139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":312783618633792,"gmtCreate":1717388921553,"gmtModify":1717393390000,"author":{"id":"4114240648215622","authorId":"4114240648215622","name":"ADM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4114240648215622","idStr":"4114240648215622"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/ANZ.AU\">$ANZ GROUP HOLDINGS LTD(ANZ.AU)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/ANZ.AU\">$ANZ GROUP HOLDINGS LTD(ANZ.AU)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$ANZ GROUP HOLDINGS LTD(ANZ.AU)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/312783618633792","isVote":1,"tweetType":1,"viewCount":1425,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":621388042699056,"gmtCreate":1792731777413,"gmtModify":1792731780179,"author":{"id":"4114240648215622","authorId":"4114240648215622","name":"ADM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4114240648215622","idStr":"4114240648215622"},"themes":[],"title":"","htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/621388042699056","repostId":"1194368123","repostType":2,"repost":{"id":"1194368123","kind":"news","weMediaInfo":{"introduction":"Focus on earnings forecast and in-depth analysis","home_visible":1,"media_name":"Earnings Agent","id":"1025659746","head_image":"https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f"},"pubTimestamp":1792687296,"share":"https://ttm.financial/m/news/1194368123?lang=en_US&edition=fundamental","pubTime":"2026-10-23 00:41","market":"hk","language":"en","title":"Earning Preview: ResMed Q1 revenue is expected to increase by 4.60%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1194368123","media":"Earnings Agent","summary":"Abstract ResMed will release first-quarter fiscal 2027 results on October 29, 2026 after market close (Post-Mkt), with investor attention centered on revenue growth, margin trajectory, and the pace...","content":"<p><h2><b>Abstract</b></h2>\nResMed will release first-quarter fiscal 2027 results on October 29, 2026 after market close (Post-Mkt), with investor attention centered on revenue growth, margin trajectory, and the pace of adjusted EPS expansion.</p>\n<p><h2><b>Market Forecast</b></h2>\nMarket expectations for the current quarter call for revenue of 1.39 billion US dollars, up 4.60% year over year, adjusted EPS of 2.67 (up 4.65% year over year), and EBIT of 471.33 million US dollars (up 1.64% year over year). Based on the previous report and recent commentary, consensus anticipates stable-to-improving profitability supported by mix and cost controls, though formal guidance for gross margin or net margin has not been issued for this quarter.</p>\n<p>ResMed’s core product engine remains anchored by the Sleep and Respiratory Care franchise, with ongoing product refresh and consumables momentum expected to support steady demand and recurring revenue from masks and supplies. The software services and digital ecosystem are the most promising segments for longer-term compounding, with last quarter’s software revenue at 172.00 million US dollars and continued product development intended to lift engagement and adherence.</p>\n<p><h2><b>Last Quarter Review</b></h2>\nIn the prior quarter, ResMed reported revenue of 1.46 billion US dollars (up 8.58% year over year), a gross profit margin of 59.41%, GAAP net profit attributable to the parent of 383.00 million US dollars, a net profit margin of 26.20%, and adjusted EPS of 2.95 (up 15.69% year over year). The company demonstrated solid operational leverage and expense discipline, which, together with revenue growth, supported the expansion in adjusted EPS.</p>\n<p>Main business momentum remained balanced: Sleep and Respiratory Care revenue reached 1.29 billion US dollars and software services delivered 172.00 million US dollars, together contributing to the 8.58% overall revenue growth and supporting resilient margins.</p>\n<p><h2><b>Current Quarter Outlook</b></h2>\n<h3><b>Sleep and Respiratory Care: Product refresh and consumables underpin recurring demand</b></h3>\nResMed’s Sleep and Respiratory Care business is poised for a seasonally normal step-down in revenue from the fiscal fourth quarter to the fiscal first quarter, with consensus projecting 1.39 billion US dollars for the current period. Product momentum is anchored by both device placements and growing consumables utilization, aided by continuous portfolio updates. The near-term catalyst set for October 28—the launch of the AirTouch F40 mask—introduces a fabric-cushioned interface designed to improve comfort and adherence; improved adherence often correlates with higher 90-day compliance rates and stronger replenishment of masks and accessories.</p>\n<p>From a margin standpoint, last quarter’s 59.41% gross profit margin reflected favorable mix and ongoing cost control. For the to-be-reported quarter, investors will look for confirmation that component cost normalization and premium-priced interfaces can help sustain margin resilience despite typical early-year seasonality. The balance between device ASPs, consumables replenishment, and logistics costs will be central to maintaining net profit and adjusted EPS trajectories. While formal guidance for gross and net margins is absent for this quarter, the market’s EBIT and EPS growth expectations imply cautious confidence in holding or modestly improving profitability.</p>\n<p>Commercially, ResMed continues to emphasize ease of use, adherence tools, and portfolio breadth to support consistent therapy engagement. The AirSense 11 family, alongside targeted mask innovations, aims to raise patient comfort and reduce abandonment. In this quarter, the incremental benefit from the F40’s introduction is expected to be modest in absolute revenue terms but meaningful in signaling a continued refresh cycle designed to reinforce the consumables revenue base.</p>\n<p><h3><b>Software and Digital Ecosystem: Focus sharpened, engagement metrics improving</b></h3>\nThe company’s software-related and digital capabilities form an increasingly important pillar of revenue quality and predictability. Last quarter’s software services revenue was 172.00 million US dollars, and the strategic simplification of the software portfolio—highlighted by the divestiture of MatrixCare—has been flagged by the buy-side and sell-side as a positive step to sharpen focus on higher-synergy, core-adjacent SaaS assets. These digital tools are designed to integrate patient engagement (via patient-facing apps) with clinician oversight (via remote monitoring platforms), creating a differentiated adherence and service loop.</p>\n<p>In the near term, the market will watch for expanding attach rates of digital services to the installed base of connected devices and masks. Even incremental improvements in adherence have a compounding effect: higher therapy compliance can lift ongoing use of masks and supplies, translating into recurring revenue momentum. The current quarter’s forecasted EPS growth of 4.65% year over year implicitly assumes continued benefits from this digital engagement model, even as headline revenue growth moderates into the mid-single digits.</p>\n<p>Operationally, a more focused software stack can also streamline go-to-market priorities, potentially improving gross margin mix by emphasizing subscription-like revenue with supportive unit economics. While formal margin guidance for software is not disclosed for the quarter, investor expectations appear to be aligned to steady growth with disciplined expense management. Over time, consistent software adoption across geographies and payer channels could help reduce variability in total company margins by stabilizing revenue streams tied to patient adherence and care management.</p>\n<p><h3><b>Key Stock Drivers This Quarter: Margin trajectory, recall headwinds, and capital deployment</b></h3>\nThree factors appear most likely to influence the stock’s performance around the print. First, margin trajectory remains a primary focus. With last quarter’s gross margin at 59.41%, the market will look for stable to slightly improved levels driven by mix (masks and supplies), selective pricing, and supply-chain tailwinds. The consensus EPS and EBIT growth rates—4.65% and 1.64% year over year respectively—imply a conservative stance on operating leverage, leaving room for upside if cost normalization proves faster or if the mix skews more favorably toward higher-margin consumables.</p>\n<p>Second, the reported class I recall affecting Astral ventilators and the subsequent decision to halt that product line for fiscal 2027 introduces a known revenue headwind. Public commentary has indicated an estimated full-year revenue impact of approximately 75.00 million US dollars related to the halt. Investors will monitor whether the company has effectively ringfenced this issue—both in revenue impact and in remediation costs—and how the product gap will be managed within the broader portfolio. While the Astral line is not the core driver of quarterly revenue, clarity on replacement strategies, timing for remediation, and the potential redeployment of resources can influence sentiment and valuation multiples.</p>\n<p>Third, capital allocation moves, particularly the 450.00 million US dollars accelerated share repurchase, play into per-share metrics and investor confidence. In the absence of a formal quarterly guidance regime, buybacks can provide support to EPS outcomes and signal conviction in medium-term cash generation. For the current quarter, the pacing and accounting of the ASR arrangement will be watched, as will any updates on the remaining authorization capacity and future repurchase intentions. Together with operating execution, capital returns shape the path of adjusted EPS and the implied free cash flow profile underpinning equity valuation.</p>\n<p>Beyond these drivers, leadership continuity and governance updates matter. Announced board changes, including the appointment of a lead director and planned retirement of a long-serving director, have been absorbed without material controversy. Investors will also track any CFO-related updates or transitions following prior retirement announcements in earlier periods, with a focus on continuity in financial policy and comfort with external stakeholder communications.</p>\n<p><h2><b>Analyst Opinions</b></h2>\nAcross recently published views in the last six months, bullish opinions outnumber bearish ones. Multiple firms have maintained or raised positive stances, citing improving gross margin trajectory, disciplined expense control, and a clearer software strategy post-portfolio streamlining. A renewed focus on core adjacencies and recurring-consumables momentum features prominently in the positive theses, with most bulls modeling mid-single-digit revenue growth and high-single-digit EPS growth over the next several years.</p>\n<p>RBC Capital Markets upgraded the shares to Outperform and highlighted a pathway to high-single-digit EPS growth over the medium term, even accounting for a potential competitive landscape shift in later fiscal years. Their constructive stance emphasized incremental gross margin recovery and solid execution in masks and supplies. This upgrade followed their earlier, more cautious posture, and signals a tangible change in conviction as margins stabilize and operating discipline improves.</p>\n<p>William Blair reiterated a Buy rating, pointing to the strategic rationale of the recent software portfolio actions, including the MatrixCare divestiture. Their view underscores a sharpened SaaS growth outlook and suggests that a tighter focus on core digital offerings can lead to more durable engagement and monetization. They also see valuation supported by the company’s recurring revenue base and the potential accretion from capital returns, including the accelerated share repurchase.</p>\n<p>KeyBanc reaffirmed an Overweight rating and raised its price target, reflecting confidence in the company’s margin and earnings trajectory. Their framework assigns value to the combined effect of improving product mix, continued device placements, and a sticky consumables stream. Baird similarly lifted its price target while keeping a positive stance, aligning with the broader bullish narrative centered on margin resilience and a product cycle that remains supportive of steady revenue growth.</p>\n<p>Neutral stances from Morgan Stanley, Citigroup, and Redburn indicate a wait-and-see approach, primarily tied to macro uncertainties, product-cycle timing, and recall-related noise. However, the absence of fresh negative calls and the presence of multiple upgrades and reaffirmations suggest that the center of gravity in the coverage universe leans constructive. The distribution of sentiment in our compiled set indicates the bull case as the majority position, with neutral voices forming the balance and little explicit bearishness currently present.</p>\n<p>In context of the to-be-reported quarter, the bullish cohort expects ResMed to deliver on the modest consensus bar—revenue growth of 4.60% year over year to 1.39 billion US dollars and adjusted EPS of 2.67, up 4.65% year over year—while demonstrating continued progress on margin stability and proof points in digital engagement. They also anticipate that the early-stage introduction of the AirTouch F40 mask could serve as a near-term signal for the ongoing consumables refresh cycle, with incremental benefits flowing more meaningfully over subsequent quarters. Additionally, the ASR is seen as a supportive factor for per-share metrics, complementing operating results.</p>\n<p>Taken together, the dominant institutional view is that ResMed is positioned to navigate the quarter’s headwinds and deliver in-line-to-slightly-better outcomes on profitability, with upside skew depending on the mix of consumables and the cadence of cost normalization. The majority stance frames the stock’s near-term setup as balanced-to-positive, contingent on reaffirming the gross margin progress seen last quarter and demonstrating steady execution in both Sleep and Respiratory Care and the digital ecosystem.</p>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Earning Preview: ResMed Q1 revenue is expected to increase by 4.60%, and institutional views are bullish</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEarning Preview: ResMed Q1 revenue is expected to increase by 4.60%, and institutional views are bullish\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1025659746\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Earnings Agent </p>\n<p class=\"h-time\">2026-10-23 00:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><h2><b>Abstract</b></h2>\nResMed will release first-quarter fiscal 2027 results on October 29, 2026 after market close (Post-Mkt), with investor attention centered on revenue growth, margin trajectory, and the pace of adjusted EPS expansion.</p>\n<p><h2><b>Market Forecast</b></h2>\nMarket expectations for the current quarter call for revenue of 1.39 billion US dollars, up 4.60% year over year, adjusted EPS of 2.67 (up 4.65% year over year), and EBIT of 471.33 million US dollars (up 1.64% year over year). Based on the previous report and recent commentary, consensus anticipates stable-to-improving profitability supported by mix and cost controls, though formal guidance for gross margin or net margin has not been issued for this quarter.</p>\n<p>ResMed’s core product engine remains anchored by the Sleep and Respiratory Care franchise, with ongoing product refresh and consumables momentum expected to support steady demand and recurring revenue from masks and supplies. The software services and digital ecosystem are the most promising segments for longer-term compounding, with last quarter’s software revenue at 172.00 million US dollars and continued product development intended to lift engagement and adherence.</p>\n<p><h2><b>Last Quarter Review</b></h2>\nIn the prior quarter, ResMed reported revenue of 1.46 billion US dollars (up 8.58% year over year), a gross profit margin of 59.41%, GAAP net profit attributable to the parent of 383.00 million US dollars, a net profit margin of 26.20%, and adjusted EPS of 2.95 (up 15.69% year over year). The company demonstrated solid operational leverage and expense discipline, which, together with revenue growth, supported the expansion in adjusted EPS.</p>\n<p>Main business momentum remained balanced: Sleep and Respiratory Care revenue reached 1.29 billion US dollars and software services delivered 172.00 million US dollars, together contributing to the 8.58% overall revenue growth and supporting resilient margins.</p>\n<p><h2><b>Current Quarter Outlook</b></h2>\n<h3><b>Sleep and Respiratory Care: Product refresh and consumables underpin recurring demand</b></h3>\nResMed’s Sleep and Respiratory Care business is poised for a seasonally normal step-down in revenue from the fiscal fourth quarter to the fiscal first quarter, with consensus projecting 1.39 billion US dollars for the current period. Product momentum is anchored by both device placements and growing consumables utilization, aided by continuous portfolio updates. The near-term catalyst set for October 28—the launch of the AirTouch F40 mask—introduces a fabric-cushioned interface designed to improve comfort and adherence; improved adherence often correlates with higher 90-day compliance rates and stronger replenishment of masks and accessories.</p>\n<p>From a margin standpoint, last quarter’s 59.41% gross profit margin reflected favorable mix and ongoing cost control. For the to-be-reported quarter, investors will look for confirmation that component cost normalization and premium-priced interfaces can help sustain margin resilience despite typical early-year seasonality. The balance between device ASPs, consumables replenishment, and logistics costs will be central to maintaining net profit and adjusted EPS trajectories. While formal guidance for gross and net margins is absent for this quarter, the market’s EBIT and EPS growth expectations imply cautious confidence in holding or modestly improving profitability.</p>\n<p>Commercially, ResMed continues to emphasize ease of use, adherence tools, and portfolio breadth to support consistent therapy engagement. The AirSense 11 family, alongside targeted mask innovations, aims to raise patient comfort and reduce abandonment. In this quarter, the incremental benefit from the F40’s introduction is expected to be modest in absolute revenue terms but meaningful in signaling a continued refresh cycle designed to reinforce the consumables revenue base.</p>\n<p><h3><b>Software and Digital Ecosystem: Focus sharpened, engagement metrics improving</b></h3>\nThe company’s software-related and digital capabilities form an increasingly important pillar of revenue quality and predictability. Last quarter’s software services revenue was 172.00 million US dollars, and the strategic simplification of the software portfolio—highlighted by the divestiture of MatrixCare—has been flagged by the buy-side and sell-side as a positive step to sharpen focus on higher-synergy, core-adjacent SaaS assets. These digital tools are designed to integrate patient engagement (via patient-facing apps) with clinician oversight (via remote monitoring platforms), creating a differentiated adherence and service loop.</p>\n<p>In the near term, the market will watch for expanding attach rates of digital services to the installed base of connected devices and masks. Even incremental improvements in adherence have a compounding effect: higher therapy compliance can lift ongoing use of masks and supplies, translating into recurring revenue momentum. The current quarter’s forecasted EPS growth of 4.65% year over year implicitly assumes continued benefits from this digital engagement model, even as headline revenue growth moderates into the mid-single digits.</p>\n<p>Operationally, a more focused software stack can also streamline go-to-market priorities, potentially improving gross margin mix by emphasizing subscription-like revenue with supportive unit economics. While formal margin guidance for software is not disclosed for the quarter, investor expectations appear to be aligned to steady growth with disciplined expense management. Over time, consistent software adoption across geographies and payer channels could help reduce variability in total company margins by stabilizing revenue streams tied to patient adherence and care management.</p>\n<p><h3><b>Key Stock Drivers This Quarter: Margin trajectory, recall headwinds, and capital deployment</b></h3>\nThree factors appear most likely to influence the stock’s performance around the print. First, margin trajectory remains a primary focus. With last quarter’s gross margin at 59.41%, the market will look for stable to slightly improved levels driven by mix (masks and supplies), selective pricing, and supply-chain tailwinds. The consensus EPS and EBIT growth rates—4.65% and 1.64% year over year respectively—imply a conservative stance on operating leverage, leaving room for upside if cost normalization proves faster or if the mix skews more favorably toward higher-margin consumables.</p>\n<p>Second, the reported class I recall affecting Astral ventilators and the subsequent decision to halt that product line for fiscal 2027 introduces a known revenue headwind. Public commentary has indicated an estimated full-year revenue impact of approximately 75.00 million US dollars related to the halt. Investors will monitor whether the company has effectively ringfenced this issue—both in revenue impact and in remediation costs—and how the product gap will be managed within the broader portfolio. While the Astral line is not the core driver of quarterly revenue, clarity on replacement strategies, timing for remediation, and the potential redeployment of resources can influence sentiment and valuation multiples.</p>\n<p>Third, capital allocation moves, particularly the 450.00 million US dollars accelerated share repurchase, play into per-share metrics and investor confidence. In the absence of a formal quarterly guidance regime, buybacks can provide support to EPS outcomes and signal conviction in medium-term cash generation. For the current quarter, the pacing and accounting of the ASR arrangement will be watched, as will any updates on the remaining authorization capacity and future repurchase intentions. Together with operating execution, capital returns shape the path of adjusted EPS and the implied free cash flow profile underpinning equity valuation.</p>\n<p>Beyond these drivers, leadership continuity and governance updates matter. Announced board changes, including the appointment of a lead director and planned retirement of a long-serving director, have been absorbed without material controversy. Investors will also track any CFO-related updates or transitions following prior retirement announcements in earlier periods, with a focus on continuity in financial policy and comfort with external stakeholder communications.</p>\n<p><h2><b>Analyst Opinions</b></h2>\nAcross recently published views in the last six months, bullish opinions outnumber bearish ones. Multiple firms have maintained or raised positive stances, citing improving gross margin trajectory, disciplined expense control, and a clearer software strategy post-portfolio streamlining. A renewed focus on core adjacencies and recurring-consumables momentum features prominently in the positive theses, with most bulls modeling mid-single-digit revenue growth and high-single-digit EPS growth over the next several years.</p>\n<p>RBC Capital Markets upgraded the shares to Outperform and highlighted a pathway to high-single-digit EPS growth over the medium term, even accounting for a potential competitive landscape shift in later fiscal years. Their constructive stance emphasized incremental gross margin recovery and solid execution in masks and supplies. This upgrade followed their earlier, more cautious posture, and signals a tangible change in conviction as margins stabilize and operating discipline improves.</p>\n<p>William Blair reiterated a Buy rating, pointing to the strategic rationale of the recent software portfolio actions, including the MatrixCare divestiture. Their view underscores a sharpened SaaS growth outlook and suggests that a tighter focus on core digital offerings can lead to more durable engagement and monetization. They also see valuation supported by the company’s recurring revenue base and the potential accretion from capital returns, including the accelerated share repurchase.</p>\n<p>KeyBanc reaffirmed an Overweight rating and raised its price target, reflecting confidence in the company’s margin and earnings trajectory. Their framework assigns value to the combined effect of improving product mix, continued device placements, and a sticky consumables stream. Baird similarly lifted its price target while keeping a positive stance, aligning with the broader bullish narrative centered on margin resilience and a product cycle that remains supportive of steady revenue growth.</p>\n<p>Neutral stances from Morgan Stanley, Citigroup, and Redburn indicate a wait-and-see approach, primarily tied to macro uncertainties, product-cycle timing, and recall-related noise. However, the absence of fresh negative calls and the presence of multiple upgrades and reaffirmations suggest that the center of gravity in the coverage universe leans constructive. The distribution of sentiment in our compiled set indicates the bull case as the majority position, with neutral voices forming the balance and little explicit bearishness currently present.</p>\n<p>In context of the to-be-reported quarter, the bullish cohort expects ResMed to deliver on the modest consensus bar—revenue growth of 4.60% year over year to 1.39 billion US dollars and adjusted EPS of 2.67, up 4.65% year over year—while demonstrating continued progress on margin stability and proof points in digital engagement. They also anticipate that the early-stage introduction of the AirTouch F40 mask could serve as a near-term signal for the ongoing consumables refresh cycle, with incremental benefits flowing more meaningfully over subsequent quarters. Additionally, the ASR is seen as a supportive factor for per-share metrics, complementing operating results.</p>\n<p>Taken together, the dominant institutional view is that ResMed is positioned to navigate the quarter’s headwinds and deliver in-line-to-slightly-better outcomes on profitability, with upside skew depending on the mix of consumables and the cadence of cost normalization. The majority stance frames the stock’s near-term setup as balanced-to-positive, contingent on reaffirming the gross margin progress seen last quarter and demonstrating steady execution in both Sleep and Respiratory Care and the digital ecosystem.</p>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RMD":"瑞思迈"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194368123","content_text":"Abstract\nResMed will release first-quarter fiscal 2027 results on October 29, 2026 after market close (Post-Mkt), with investor attention centered on revenue growth, margin trajectory, and the pace of adjusted EPS expansion.\nMarket Forecast\nMarket expectations for the current quarter call for revenue of 1.39 billion US dollars, up 4.60% year over year, adjusted EPS of 2.67 (up 4.65% year over year), and EBIT of 471.33 million US dollars (up 1.64% year over year). Based on the previous report and recent commentary, consensus anticipates stable-to-improving profitability supported by mix and cost controls, though formal guidance for gross margin or net margin has not been issued for this quarter.\nResMed’s core product engine remains anchored by the Sleep and Respiratory Care franchise, with ongoing product refresh and consumables momentum expected to support steady demand and recurring revenue from masks and supplies. The software services and digital ecosystem are the most promising segments for longer-term compounding, with last quarter’s software revenue at 172.00 million US dollars and continued product development intended to lift engagement and adherence.\nLast Quarter Review\nIn the prior quarter, ResMed reported revenue of 1.46 billion US dollars (up 8.58% year over year), a gross profit margin of 59.41%, GAAP net profit attributable to the parent of 383.00 million US dollars, a net profit margin of 26.20%, and adjusted EPS of 2.95 (up 15.69% year over year). The company demonstrated solid operational leverage and expense discipline, which, together with revenue growth, supported the expansion in adjusted EPS.\nMain business momentum remained balanced: Sleep and Respiratory Care revenue reached 1.29 billion US dollars and software services delivered 172.00 million US dollars, together contributing to the 8.58% overall revenue growth and supporting resilient margins.\nCurrent Quarter Outlook\nSleep and Respiratory Care: Product refresh and consumables underpin recurring demand\nResMed’s Sleep and Respiratory Care business is poised for a seasonally normal step-down in revenue from the fiscal fourth quarter to the fiscal first quarter, with consensus projecting 1.39 billion US dollars for the current period. Product momentum is anchored by both device placements and growing consumables utilization, aided by continuous portfolio updates. The near-term catalyst set for October 28—the launch of the AirTouch F40 mask—introduces a fabric-cushioned interface designed to improve comfort and adherence; improved adherence often correlates with higher 90-day compliance rates and stronger replenishment of masks and accessories.\nFrom a margin standpoint, last quarter’s 59.41% gross profit margin reflected favorable mix and ongoing cost control. For the to-be-reported quarter, investors will look for confirmation that component cost normalization and premium-priced interfaces can help sustain margin resilience despite typical early-year seasonality. The balance between device ASPs, consumables replenishment, and logistics costs will be central to maintaining net profit and adjusted EPS trajectories. While formal guidance for gross and net margins is absent for this quarter, the market’s EBIT and EPS growth expectations imply cautious confidence in holding or modestly improving profitability.\nCommercially, ResMed continues to emphasize ease of use, adherence tools, and portfolio breadth to support consistent therapy engagement. The AirSense 11 family, alongside targeted mask innovations, aims to raise patient comfort and reduce abandonment. In this quarter, the incremental benefit from the F40’s introduction is expected to be modest in absolute revenue terms but meaningful in signaling a continued refresh cycle designed to reinforce the consumables revenue base.\nSoftware and Digital Ecosystem: Focus sharpened, engagement metrics improving\nThe company’s software-related and digital capabilities form an increasingly important pillar of revenue quality and predictability. Last quarter’s software services revenue was 172.00 million US dollars, and the strategic simplification of the software portfolio—highlighted by the divestiture of MatrixCare—has been flagged by the buy-side and sell-side as a positive step to sharpen focus on higher-synergy, core-adjacent SaaS assets. These digital tools are designed to integrate patient engagement (via patient-facing apps) with clinician oversight (via remote monitoring platforms), creating a differentiated adherence and service loop.\nIn the near term, the market will watch for expanding attach rates of digital services to the installed base of connected devices and masks. Even incremental improvements in adherence have a compounding effect: higher therapy compliance can lift ongoing use of masks and supplies, translating into recurring revenue momentum. The current quarter’s forecasted EPS growth of 4.65% year over year implicitly assumes continued benefits from this digital engagement model, even as headline revenue growth moderates into the mid-single digits.\nOperationally, a more focused software stack can also streamline go-to-market priorities, potentially improving gross margin mix by emphasizing subscription-like revenue with supportive unit economics. While formal margin guidance for software is not disclosed for the quarter, investor expectations appear to be aligned to steady growth with disciplined expense management. Over time, consistent software adoption across geographies and payer channels could help reduce variability in total company margins by stabilizing revenue streams tied to patient adherence and care management.\nKey Stock Drivers This Quarter: Margin trajectory, recall headwinds, and capital deployment\nThree factors appear most likely to influence the stock’s performance around the print. First, margin trajectory remains a primary focus. With last quarter’s gross margin at 59.41%, the market will look for stable to slightly improved levels driven by mix (masks and supplies), selective pricing, and supply-chain tailwinds. The consensus EPS and EBIT growth rates—4.65% and 1.64% year over year respectively—imply a conservative stance on operating leverage, leaving room for upside if cost normalization proves faster or if the mix skews more favorably toward higher-margin consumables.\nSecond, the reported class I recall affecting Astral ventilators and the subsequent decision to halt that product line for fiscal 2027 introduces a known revenue headwind. Public commentary has indicated an estimated full-year revenue impact of approximately 75.00 million US dollars related to the halt. Investors will monitor whether the company has effectively ringfenced this issue—both in revenue impact and in remediation costs—and how the product gap will be managed within the broader portfolio. While the Astral line is not the core driver of quarterly revenue, clarity on replacement strategies, timing for remediation, and the potential redeployment of resources can influence sentiment and valuation multiples.\nThird, capital allocation moves, particularly the 450.00 million US dollars accelerated share repurchase, play into per-share metrics and investor confidence. In the absence of a formal quarterly guidance regime, buybacks can provide support to EPS outcomes and signal conviction in medium-term cash generation. For the current quarter, the pacing and accounting of the ASR arrangement will be watched, as will any updates on the remaining authorization capacity and future repurchase intentions. Together with operating execution, capital returns shape the path of adjusted EPS and the implied free cash flow profile underpinning equity valuation.\nBeyond these drivers, leadership continuity and governance updates matter. Announced board changes, including the appointment of a lead director and planned retirement of a long-serving director, have been absorbed without material controversy. Investors will also track any CFO-related updates or transitions following prior retirement announcements in earlier periods, with a focus on continuity in financial policy and comfort with external stakeholder communications.\nAnalyst Opinions\nAcross recently published views in the last six months, bullish opinions outnumber bearish ones. Multiple firms have maintained or raised positive stances, citing improving gross margin trajectory, disciplined expense control, and a clearer software strategy post-portfolio streamlining. A renewed focus on core adjacencies and recurring-consumables momentum features prominently in the positive theses, with most bulls modeling mid-single-digit revenue growth and high-single-digit EPS growth over the next several years.\nRBC Capital Markets upgraded the shares to Outperform and highlighted a pathway to high-single-digit EPS growth over the medium term, even accounting for a potential competitive landscape shift in later fiscal years. Their constructive stance emphasized incremental gross margin recovery and solid execution in masks and supplies. This upgrade followed their earlier, more cautious posture, and signals a tangible change in conviction as margins stabilize and operating discipline improves.\nWilliam Blair reiterated a Buy rating, pointing to the strategic rationale of the recent software portfolio actions, including the MatrixCare divestiture. Their view underscores a sharpened SaaS growth outlook and suggests that a tighter focus on core digital offerings can lead to more durable engagement and monetization. They also see valuation supported by the company’s recurring revenue base and the potential accretion from capital returns, including the accelerated share repurchase.\nKeyBanc reaffirmed an Overweight rating and raised its price target, reflecting confidence in the company’s margin and earnings trajectory. Their framework assigns value to the combined effect of improving product mix, continued device placements, and a sticky consumables stream. Baird similarly lifted its price target while keeping a positive stance, aligning with the broader bullish narrative centered on margin resilience and a product cycle that remains supportive of steady revenue growth.\nNeutral stances from Morgan Stanley, Citigroup, and Redburn indicate a wait-and-see approach, primarily tied to macro uncertainties, product-cycle timing, and recall-related noise. However, the absence of fresh negative calls and the presence of multiple upgrades and reaffirmations suggest that the center of gravity in the coverage universe leans constructive. The distribution of sentiment in our compiled set indicates the bull case as the majority position, with neutral voices forming the balance and little explicit bearishness currently present.\nIn context of the to-be-reported quarter, the bullish cohort expects ResMed to deliver on the modest consensus bar—revenue growth of 4.60% year over year to 1.39 billion US dollars and adjusted EPS of 2.67, up 4.65% year over year—while demonstrating continued progress on margin stability and proof points in digital engagement. They also anticipate that the early-stage introduction of the AirTouch F40 mask could serve as a near-term signal for the ongoing consumables refresh cycle, with incremental benefits flowing more meaningfully over subsequent quarters. Additionally, the ASR is seen as a supportive factor for per-share metrics, complementing operating results.\nTaken together, the dominant institutional view is that ResMed is positioned to navigate the quarter’s headwinds and deliver in-line-to-slightly-better outcomes on profitability, with upside skew depending on the mix of consumables and the cadence of cost normalization. The majority stance frames the stock’s near-term setup as balanced-to-positive, contingent on reaffirming the gross margin progress seen last quarter and demonstrating steady execution in both Sleep and Respiratory Care and the digital ecosystem.","news_type":1,"symbols_score_info":{"RMD":1}},"isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":356332767183088,"gmtCreate":1728004779183,"gmtModify":1728004781545,"author":{"id":"4114240648215622","authorId":"4114240648215622","name":"ADM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4114240648215622","idStr":"4114240648215622"},"themes":[],"title":"","htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/356332767183088","repostId":"2472864773","repostType":2,"isVote":1,"tweetType":1,"viewCount":1254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":356331204743312,"gmtCreate":1728004480911,"gmtModify":1728006360250,"author":{"id":"4114240648215622","authorId":"4114240648215622","name":"ADM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4114240648215622","idStr":"4114240648215622"},"themes":[],"title":"","htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/356331204743312","repostId":"2472864773","repostType":2,"isVote":1,"tweetType":1,"viewCount":1021,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":348282003079272,"gmtCreate":1726035917488,"gmtModify":1726037056035,"author":{"id":"4114240648215622","authorId":"4114240648215622","name":"ADM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4114240648215622","idStr":"4114240648215622"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/ANZ.AU\">$ANZ GROUP HOLDINGS LTD(ANZ.AU)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/ANZ.AU\">$ANZ GROUP HOLDINGS LTD(ANZ.AU)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$ANZ GROUP HOLDINGS LTD(ANZ.AU)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/348282003079272","isVote":1,"tweetType":1,"viewCount":1570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":348282324160656,"gmtCreate":1726035906464,"gmtModify":1726035923992,"author":{"id":"4114240648215622","authorId":"4114240648215622","name":"ADM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4114240648215622","idStr":"4114240648215622"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/ANZ.AU\">$ANZ GROUP HOLDINGS LTD(ANZ.AU)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/ANZ.AU\">$ANZ GROUP HOLDINGS LTD(ANZ.AU)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$ANZ GROUP HOLDINGS LTD(ANZ.AU)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/348282324160656","isVote":1,"tweetType":1,"viewCount":1139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":312783618633792,"gmtCreate":1717388921553,"gmtModify":1717393390000,"author":{"id":"4114240648215622","authorId":"4114240648215622","name":"ADM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4114240648215622","idStr":"4114240648215622"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/ANZ.AU\">$ANZ GROUP HOLDINGS LTD(ANZ.AU)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/ANZ.AU\">$ANZ GROUP HOLDINGS LTD(ANZ.AU)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$ANZ GROUP HOLDINGS LTD(ANZ.AU)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/312783618633792","isVote":1,"tweetType":1,"viewCount":1425,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}